Synthesis and study of some new N-substituted imide derivatives as potential antibacterial agents

[1] Braña, M. F., Domínguez, G., Sáez, B., Romerdahl, C., Robinson, S., & Barlozzari, T. (2002). Synthesis and antitumour activity of new dendritic polyamines-(imide-DNA-intercalator) conjugates: potent Lck inhibitors. European Journal of Medicinal Chemistry, 37, 541–551. DOI: 10.1016/S0223-5234(02)01362-4. http://dx.doi.org/10.1016/S0223-5234(02)01362-410.1016/S0223-5234(02)01362-4Suche in Google Scholar

[2] Cegła, M. T., Boksa, J., Chojnacka-Wójcik, E., & Misztal, S. (1996). 4-Aryl-1-piperazinylalkyl derivatives of 1,2,3,4-tetrahydro-β-carboline ring system. Synthesis and preliminary in vivo studies. Die Pharmazie, 51, 932–936. Suche in Google Scholar

[3] Clar, E. (1931). Zur Kenntnis mehrkerniger aromatischer Kohlenwasserstoffe und ihrer Abkömmlinge, XI. Mitteil.: Über die Konstitution des Anthracens, II.: Bemerkungen zu einer Arbeit von Otto Diels und Kurt Alder. Berichte der Deutschen Chemischen Gesellschaft, 64, 2194–2200. DOI: 10.1002/cber.19310640854. http://dx.doi.org/10.1002/cber.1931064085410.1002/cber.19310640854Suche in Google Scholar

[4] Cruickshank, R., Duguid, J. P., Marmion, B. P., & Swain, R. H. A. (Eds.) (1973). Medical Microbiology (12th ed., vol. 2, pp. 196–202). Edinburgh, UK: Churchill Livingstone. Suche in Google Scholar

[5] Desai, R. A., & Samant, S. D. (2000). Preparation of N-[ω-(4-aryl-1-piperazinyl)ethyl/propyl]-3-hydroxyphthalimides. Indian Journal of Chemistry, 39B, 455–457. Suche in Google Scholar

[6] Fernández Braña, M., Fernández, A., Garrido, M., López-Rodríguez, M. L., Morcillo, M. J., & Sanz, A. M. (1989). Synthesis, structure and cytostatic activity of a series of N-substituted 3,4-diphenyl-1H-pyrrole-2,5-diones. Chemical & Pharmaceutical Bulletin, 37, 2710–2712. 10.1248/cpb.37.2710Suche in Google Scholar

[7] Goldfarb, D. S. (2009). Method for altering the lifespan of eukaryotic organisms. U.S. Patent Application Publication No. US 2009/0163545 A1. Alexandria, VA, USA: United States Patent and Trademark Office. Suche in Google Scholar

[8] Jindal, D. P., Bedi, V., Jit, B., Karkra, N., Guleria, S., Bansal, R., Palusczak, A., & Hartmann, R. W. (2005). Synthesis and study of some new N-substituted imide derivatives as potential anticancer agents. Il Farmaco, 60, 283–290. DOI: 10.1016/j.farmac.2005.01.011. http://dx.doi.org/10.1016/j.farmac.2005.01.01110.1016/j.farmac.2005.01.011Suche in Google Scholar

[9] Khadilkar, B. M., & Samant, S. D. (1993). Synthesis and pharmacology of 2-[3-(4-aryl-1-piperazinyl)-2-hydroxypropyl/3-oxopropyl/propoxy]-1H-isoindole-1,3(2H)-diones. Indian Journal of Chemistry, 32B, 1137–1142. Suche in Google Scholar

[10] Khadilkar, B. M., & Samant, S. D. (1986). Synthesis and pharmacology of some 2-[3-(4-aryl-1-piperazinyl)propyl]-1H-benz[d]isoquinoline-1,3-(2H)-diones/2,5-pyrrolidones. Journal of Indian Chemical Society, 63, 529–530. Suche in Google Scholar

[11] Kitahonoki, K., & Kido, R. (1975). N,N′-Alkylen-bis-dibenzobicyclo-octanopyrrolidin-Verbindungen und ihre Herstellung. German Patent No. DE 1695796. Munich, Germany: German Patent and Trademark Office. Suche in Google Scholar

[12] Kitahonoki, K., & Kido, R. (1970). N,N′-alkylene-bis-dibenzobicyclooctanopyrrolidine compounds and production thereof. U.S. Patent No. 3,513,174. Arlington, VA, USA: U.S. Patent Office. Suche in Google Scholar

[13] Kitamogi, K., & Kido, R. (1967). N,N′-Alkylidenebis(acid imides). Japan Patent No. JP 9574. Tokyo, Japan: Japan Patent Office. Suche in Google Scholar

[14] Kossakowski, J., & Jarocka, M. (2001). Synthesis of new N-substituted cyclic imides with an expected anxiolytic activity. XVII. Derivatives of 1-ethoxybicyclo[2.2.2]-oct-5-one-2,3-dicarboximide. Il Farmaco, 56, 785–789. DOI: 10.1016/S0014-827X(01)01144-2. http://dx.doi.org/10.1016/S0014-827X(01)01144-210.1016/S0014-827X(01)01144-2Suche in Google Scholar

[15] Légora Machado, A., Moreira Lima, L., Araújo, J. X., Jr., Fraga, C. A. M., Gonçalves Koatz, V. L., & Barreiro, E. J. (2005). Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorganic & Medicinal Chemistry Letters, 15, 1169–1172. DOI: 10.1016/j.bmcl.2004.12.012. http://dx.doi.org/10.1016/j.bmcl.2004.12.01210.1016/j.bmcl.2004.12.012Suche in Google Scholar PubMed

[16] Saikia, R., Singh, A. K., & Bhattacharjee, G. (1988). N-(Sulfony1oxy)phthalimides and analogues are potent inactivators. Indian Journal of Chemistry, 27A, 790–793. Suche in Google Scholar

[17] Salvati, M. E., Balog, A., Shan, W., Wei, D. D., Pickering, D., Attar, R. M., Geng, J., Rizzo, C. A., Gottardis, M. M., Weinmann, R., Krystek, S. R., Sack, J., An, Y., & Kish, K. (2005). Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 15, 271–276. DOI: 10.1016/j.bmcl.2004.10.085. http://dx.doi.org/10.1016/j.bmcl.2004.10.08510.1016/j.bmcl.2004.10.085Suche in Google Scholar PubMed

[18] Samant, S. D., & Kulkarni, R. A. (1979). Synthesis and pharmacology of N-(N 4-aryl-N 1-piprazinylalkyl)phthalimides: CNS depressants. Journal of Indian Chemical Society, 56, 1002. Suche in Google Scholar

[19] Sieklucka-Dziuba, M., Rajtar, G., & Kleinrok, Z. (1995). Some pharmacological properties and cumulative, subchronic and chronic toxicity of 9-methyl-2-[3-(4-phenyl-1-piperazinylpropyl)]-1,2,3,4-tetrahydro-β-carbolin-1-one (B-193). Polish Journal of Pharmacology, 47, 305–311. Suche in Google Scholar

[20] Staniek, P., & Stoll, K. (1995). Imide nucleating agents for polymers. German Patent Application No. DE 19520262. Munich, Germany: German Patent Office. Suche in Google Scholar

[21] Suzuki, K., Nagasawa, H., Uto, Y., Sugimoto, Y., Noguchi, K., Wakida, M., Wierzba, K., Terada, T., Asao, T., Yamada, Y., Kitazato, K., & Hori, H. (2005). Napthalimidobenzamide DB-51630: a novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity. Bioorganic & Medicinal Chemistry, 13, 4014–4021. DOI: 10.1016/j.bmc.2005.03.053. http://dx.doi.org/10.1016/j.bmc.2005.03.05310.1016/j.bmc.2005.03.053Suche in Google Scholar PubMed

[22] Weber, E., Finge, S., & Csoeregh, I. (1991). Modular design of hosts involving a rigid succinimide framework and N-bonded lateral groups. Crystalline inclusion properties and crystal structures of inclusion compounds with dioxane, MeOH, and DMF. Journal of Organic Chemistry, 56, 7281–7288. DOI: 10.1021/jo00026a018. http://dx.doi.org/10.1021/jo00026a01810.1021/jo00026a018Suche in Google Scholar

[23] Wehner, W., Michaelis, K. P., & Schneider, R. (1981). Alkanolamid-beta-ketocarbonsäureester und ihre Verwendung zur Stabilisierung von chlorhaltigen Thermoplasten. European Patent Application No. EP 0022749. Munich, Germany: European Patent Office. Suche in Google Scholar

[24] Wiczyńska, B., Chojnacka-Wójcik, E., Rokosz-Pelc, A., Mazela, H., & Przegaliński, E. (1989). Antiserotonin activity of 9-methyl-2-[3-(4-phenyl-1-piperazinylpropyl)]-1,2,3,4-tetrahydro-β-carbolin-1-one (B-193). Polish Journal of Pharmacology and Pharmacy, 41, 169–181. Suche in Google Scholar

[25] Wu, Y.-H., Smith, K. R., Rayburn, J.W., & Kissel, J.W. (1969). Psychosedative agents. N-(4-phenyl-1-piperazinylalkyl)-substituted cyclic imides. Journal of Medicinal Chemistry, 12, 876–881. DOI: 10.1021/jm00305a037. http://dx.doi.org/10.1021/jm00305a03710.1021/jm00305a037Suche in Google Scholar PubMed